Researchers from the University of Cape Town’s (UCT) South African Tuberculosis Vaccine Initiative (SATVI), the Center for Global Infectious Disease Research – Seattle, US, and a consortium of collaborators have developed and validated a new test for tuberculosis (TB).
Named RISK6, the new blood-based test can identify healthy individuals who are at risk of developing TB. It can also identify people with subclinical or clinical disease and help understand how well a patient would respond to the treatment.
The test, which can be applied to capillary blood collected by finger prick, is currently validated in seven cohorts across two continents.
